

ARRAY BIOPHARMA INC  
Form 8-K  
June 06, 2016

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 4, 2016**

**Array BioPharma Inc.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

**001-16633**

**84-1460811**

*(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)*

**3200 Walnut Street, Boulder, Colorado 80301**

*(Address of principal executive offices, including Zip Code)*

**(303) 381-6600**

*(Registrant's telephone number, including area code)*

*(Former name or former address, if changed since last report)*

Edgar Filing: ARRAY BIOPHARMA INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

**Item 8.01 Other Events.**

On June 4, 2016, Array issued two press releases announcing additional data from a Phase 2 study of encorafenib-based regimens in patients with BRAF-mutant colorectal cancer and initiation of a Phase 3 trial of encorafenib and binimetinib in patients with BRAF-mutant colorectal cancer.

Copies of the press releases are attached to this Form 8-K as Exhibit 99.1, Exhibit 99.2 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

**Exhibit No. Description**

99.1	Press release announcing additional data from Phase 2 study of encorafenib-based regimens in patients with BRAF-mutant colorectal cancer dated June 4, 2016
------	---

99.2	Press release announcing initiation of a Phase 3 trial of encorafenib and binimetinib in patients with BRAF-mutant colorectal cancer dated June 4, 2016
------	---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2016 Array BioPharma Inc.

By: /s/ David Horin  
David Horin  
Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Press release announcing additional data from Phase 2 study of encorafenib-based regimens in patients with BRAF-mutant colorectal cancer dated June 4, 2016

99.2 Press release announcing initiation of a Phase 3 trial of encorafenib and binimetinib in patients with BRAF-mutant colorectal cancer dated June 4, 2016

4